Don't know about that mate, it remains to be seen.I just want to see no more hype and ramping of this company, just steady share price appreciation directly proportional to revenues.Have a good day!
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%